The anti-CD38 immunotherapy daratumumab (Darzalex) has been approved by the TGA for use in multiple myeloma.
The therapy can be used in combination with existing therapies for patients with multiple myeloma who have received at least one therapy, or as a single agent for patients who have received three lines of therapy or who do not respond to standard therapies.